MARKET

VXRT

VXRT

Vaxart Inc
NASDAQ
2.240
+0.090
+4.19%
After Hours: 2.200 -0.04 -1.79% 16:22 10/04 EDT
OPEN
2.170
PREV CLOSE
2.150
HIGH
2.255
LOW
2.155
VOLUME
2.93M
TURNOVER
0
52 WEEK HIGH
8.13
52 WEEK LOW
2.015
MARKET CAP
283.37M
P/E (TTM)
-3.0287
1D
5D
1M
3M
1Y
5Y
Moderna, Novavax hit 52-week lows
The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:<a href="https://seekingalpha.com/symbol/MRNA?utm_medium=referral&utm_source=webull.com" title="Mod...
Seekingalpha · 5d ago
EU drug regulator's chief medical officer says COVID-19 pandemic still ongoing
A European drug regulator official on Tuesday cautioned that the COVID-19 pandemic was still ongoing, as countries across the continent prepare to rollout subvariant adapted vaccines for a fall and winter immunization campaign."We in Europ...
Seekingalpha · 09/20 16:26
Why Vaxart Shares Are Falling
Vaxart Inc (NASDAQ: VXRT) shares are trading lower by 6.76% to $2.42 during Monday&#39;s trading session. Shares of several vaccine companies at large are trading lower possibly after President Biden in a &#39;60 Minutes&#39; interview said the Covid pandemic is over.
Benzinga · 09/19 17:10
COVID-19 vaccine makers fall as Biden says pandemic is over
Leading COVID-19 vaccine developers are on the decline in the morning hours Monday after President Joe Biden said that the pandemic is a thing of the past despite ongoing concerns related to the virus.  "The pandemic is over," he <a href="...
Seekingalpha · 09/19 15:12
Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $8
Cantor Fitzgerald analyst Charles Duncan maintains Vaxart (NASDAQ:VXRT) with a Overweight and lowers the price target from $11 to $8.
Benzinga · 09/02 12:33
Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating
Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating
MT Newswires · 09/02 08:23
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Benzinga · 09/01 22:36
What Is Going on With Vaxart (VXRT) Stock Today?
Investor Place · 09/01 18:11
More
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.